ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Muscle Biology, Myositis and Myopathies Poster

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 294
A Decline in Pulmonary Function over One Year Predicts Outcome in Myositis-Associated Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 304
Abnormal Pulmonary Function Tests, Interstitial Lung Disease, and Lung Function Decline in Patients with Classic and Clinically Amyopathic Dermatomyositis
9:00AM-11:00AM
Abstract Number: 283
Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
9:00AM-11:00AM
Abstract Number: 282
Angiogenesis in Fasciitis Associated with Dermatomyositis
9:00AM-11:00AM
Abstract Number: 290
Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
9:00AM-11:00AM
Abstract Number: 300
Causes of Creatine Kinase Levels Greater Than 1,000 IU/L in Patients Referred to Rheumatology
9:00AM-11:00AM
Abstract Number: 291
Correlations Between Muscle-MRI, Muscle Strength and Creatine Kinase Levels in the Anti-Synthetase Syndrome; A Comparative, Cross-Sectional Study
9:00AM-11:00AM
Abstract Number: 296
Different Patterns of Involvement of Thigh Muscles in Dermatomyositis and Polymyositis Using Fat-Suppressed Magnetic Resonance Sequences
9:00AM-11:00AM
Abstract Number: 301
Economic Burden of Sporadic Inclusion Body Myositis in the United States of America: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 289
Evaluation of Usefulness of Krebs Von Den Lungen-6 As a Biomarker of Interstitial Lung Disease with Polymyositis and Dermatomyositis Including in the Short Time Course after Treatment
9:00AM-11:00AM
Abstract Number: 281
Health Related Quality of Life Is Reduced in Adult Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 297
How Useful Is Magnetic Resonance Imaging (MRI) in Monitoring Patients with Myositis?
9:00AM-11:00AM
Abstract Number: 287
Interleukin-35 in Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 298
Investigating the Pathogenic Role of ER Stress Pathway Activation in the Idiopathic Inflammatory Myopathies (IIM): Skeletal Muscle Cells As a Source of Cytokines (Myokines)
9:00AM-11:00AM
Abstract Number: 306
Investigating the Pathogenic Role of ER Stress Pathways in the Idiopathic Inflammatory Myopathies (IIM): Interrogating the Role of Micro-RNA 133a As an Important Regulator of ER Stress Activation
9:00AM-11:00AM
Abstract Number: 293
Measurement of Advanced Glycation Endproducts in the Skin of Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 303
Mining RNA-Seq of Peripheral Blood Mononuclear Cells from JDM Alone Compared with JDM Plus Psoriasis for Biomarkers of Disease Activity
9:00AM-11:00AM
Abstract Number: 288
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
9:00AM-11:00AM
Abstract Number: 308
Nailfold Capillaroscopy in Patients with Early Onset-Dermatomyositis
9:00AM-11:00AM
Abstract Number: 292
Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
9:00AM-11:00AM
Abstract Number: 309
Plasma Levels of Heat Shock Protein 90 Are Increased in Idiopathic Inflammatory Myopathies and Correlate with Disease Activity, Skeletal Muscle, Heart and Lung Involvement
9:00AM-11:00AM
Abstract Number: 295
Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index Among Dermatologists, Rheumatologists, and Neurologists
9:00AM-11:00AM
Abstract Number: 302
Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis
9:00AM-11:00AM
Abstract Number: 307
Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches
9:00AM-11:00AM
Abstract Number: 299
Subcutaneous Edema, Distal Weakness and Dysphagia Associated with the NXP2 Antibody
9:00AM-11:00AM
Abstract Number: 305
The “Sleeve Sign”� in Dermatomyositis
9:00AM-11:00AM
Abstract Number: 280
The Fascia Is a Target Organ of Inflammation in Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 285
Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 284
Validation of the Sporadic Inclusion Body Myositis Physical Functioning Assessment

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology